From nature-derived Natural Exosomes to the world’s smallest miPDRN,
XenoHelix goes beyond the limitations of conventional nucleic acid technologies to create new value.
We have realized nature’s remarkable delivery power (exosomes, miRNA, miPDRN) through innovative technology.
Designed at the scale of miRNA, which was brought back into the spotlight with the 2024 Nobel Prize in Physiology or Medicine, miPDRN has been developed. It overcomes the limitations of high-molecular-weight PDRN, rapidly penetrating deep into the skin to act on A2A receptors.
Conventional callus-derived exosomes lack plant-specific active compounds due to dark-condition cultivation.
Natural Exosome is directly isolated from plants grown under photosynthetic conditions,
ensuring a high concentration of natural phytochemicals.
Cosmetic Lineup Crafted by Nature and Science
Formulated with high concentrations of Natural Exosomes derived from red ginseng and centella asiatica. A solution for rapid skin recovery and soothing damaged skin.
Formulated with high concentrations of Natural Exosomes derived from red ginseng and centella asiatica. Helps promote thicker, healthier hair.
A new skincare experience powered by the world’s smallest miPDRN at 50,000 ppm.
Ultra-Sensitive Total RNA Detection Platform Beyond Limits
The Core (The Beginning of True Data)
The truth of data is determined by purity
The most perfect starting point of data discovered within chaos.
By eliminating 99.9% of impurities, it secures uncompromising high-purity RNA even from hard-to-degrade samples.
The Innovation (Detecting Invisible Risks)
The convergence of innovation that identifies unseen risks
With precision that detects even a single base-pair difference, it brings new hope for the early diagnosis of intractable diseases. Delivering clear and accurate results in just one hour without complex procedures.
The Impact (Technology for a Brighter Tomorrow)
Beyond innovation, diagnosing the future of humanity
Replacing expensive and invasive conventional tests with blood-based, non-invasive early diagnostics. From MASLD to neurological disorders, it establishes a new standard in precision medicine with a validated pipeline.
